Associations - everolimus

No biomarker	Astrocytoma	No biomarker	Astrocytoma	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
No biomarker	Meningioma	No biomarker	Meningioma	bevacizumab + everolimus Sensitive: A2 - Guideline bevacizumab + everolimus Sensitive : A2	bevacizumab + everolimus Sensitive: A2 - Guideline bevacizumab + everolimus Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	sorafenib + everolimus Sensitive: A2 - Guideline sorafenib + everolimus Sensitive : A2	sorafenib + everolimus Sensitive: A2 - Guideline sorafenib + everolimus Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	everolimus + letrozole Sensitive: A2 - Guideline everolimus + letrozole Sensitive : A2	everolimus + letrozole Sensitive: A2 - Guideline everolimus + letrozole Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	bevacizumab + everolimus Sensitive: A2 - Guideline bevacizumab + everolimus Sensitive : A2	bevacizumab + everolimus Sensitive: A2 - Guideline bevacizumab + everolimus Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	everolimus + lenvatinib Sensitive: A2 - Guideline everolimus + lenvatinib Sensitive : A2	everolimus + lenvatinib Sensitive: A2 - Guideline everolimus + lenvatinib Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
ESR1 wild-type + HR positive	HER2 Negative Breast Cancer	ESR1 wild-type + HR positive	HER2 Negative Breast Cancer	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	everolimus Sensitive: B - Late Trials everolimus Sensitive : B	everolimus Sensitive: B - Late Trials everolimus Sensitive : B
PTEN deletion	HER2 Positive Breast Cancer	PTEN deletion	HER2 Positive Breast Cancer	everolimus Sensitive: B - Late Trials everolimus Sensitive : B	everolimus Sensitive: B - Late Trials everolimus Sensitive : B
MTOR mutation	Renal Cell Carcinoma	MTOR mutation	Renal Cell Carcinoma	everolimus Sensitive: C2 – Inclusion Criteria everolimus Sensitive : C2	everolimus Sensitive: C2 – Inclusion Criteria everolimus Sensitive : C2
FLCN mutation	Renal Cell Carcinoma	FLCN mutation	Renal Cell Carcinoma	everolimus Sensitive: C2 – Inclusion Criteria everolimus Sensitive : C2	everolimus Sensitive: C2 – Inclusion Criteria everolimus Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	everolimus Sensitive: C2 – Inclusion Criteria everolimus Sensitive : C2	everolimus Sensitive: C2 – Inclusion Criteria everolimus Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	everolimus + BI-836845 Sensitive: C3 – Early Trials everolimus + BI-836845 Sensitive : C3	everolimus + BI-836845 Sensitive: C3 – Early Trials everolimus + BI-836845 Sensitive : C3
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
PALB2 mutation	Triple Negative Breast Cancer	PALB2 mutation	Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
TSC2 overexpression	Hepatocellular Cancer	TSC2 overexpression	Hepatocellular Cancer	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	everolimus + letrozole + leuprolide acetate Sensitive: C3 – Early Trials everolimus + letrozole + leuprolide acetate Sensitive : C3	everolimus + letrozole + leuprolide acetate Sensitive: C3 – Early Trials everolimus + letrozole + leuprolide acetate Sensitive : C3

everolimus

Associations
(138)

Associations
(138)

everolimus

Associations(138)

Associations(138)

Associations
(138)

Associations
(138)